Old and new inhibitors of quinone reductase 2

Chemico-Biological Interactions

Volumn 186, Issue 2, 2010, Pages 103-109

  Ferry, Gilles ^a   Hecht, Sabrina ^a   Berger, Sylvie ^a   Moulharat, Natacha ^a   Coge, Francis ^a   Guillaumet, Gérald ^b   Leclerc, Véronique ^c   Yous, Saïd ^c   Delagrange, Philippe ^d   Boutin, Jean A ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c UNIV LILLE   (France)

^d INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Inhibitors; Melatonin; Menadione; Quinone reductase 2

Indexed keywords

MELATONIN; N [2 (2METHOXY 6H DIPYRIDO[2,3 A:3,2 E]PYRROLIZIN 11 YL)ETHYL] 2 FURAMIDE; OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; QUINONE REDUCTASE 2; RESVERATROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CHEMICAL ANALYSIS; ENZYME INHIBITION; IC 50; INHIBITION KINETICS; NONHUMAN;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; ENZYME INHIBITORS; FURANS; HUMANS; KINETICS; MELATONIN; PYRIDINES; PYRROLIZIDINE ALKALOIDS; QUINONE REDUCTASES; RECEPTORS, MELATONIN; RECOMBINANT PROTEINS; SPODOPTERA; STILBENES; SUBSTRATE SPECIFICITY;

EID: 77953542372     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.04.006     Document Type: Article

References (43)

1. Liao S., Dulaney J.T., Williams-Ashley H.G. Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide. J. Biol. Chem. 1962, 237:2981-2987.
2. Liao S., Williams-Ashley H.G. Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide. Biochem. Biophys. Res. Commun. 1961, 4:208-213.
3. Liao S., Williams-Ashley H.G. Inhibition of the enzymic oxidation of some dihydropyridines by polycyclic aromatic hydrocarbons. Biochem. Pharmacol. 1961, 6:53-54.
4. Jaiswal A.K. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 1991, 30:10647-10653.
5. Zhao Q., Yang X.L., Holtzclaw W.D., Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1669-1674.
6. Gong X., Gutala R., Jaiswal A.K. Quinone oxidoreductases and vitamin K metabolism. Vitam. Horm. 2008, 78:85-101.
7. Wu K., Knox R., Sun X.Z., Joseph P., Jaiswal A.K., Zhang D., Deng P.S., Chen S. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 1997, 347:221-228.
8. Jamieson D, Tung A.T., Knox R.J., Boddy A.V. Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. Br. J. Cancer 2006, 95:1229-1233.
9. Foster C.E., Bianchet M.A., Talalay P., Zhao Q., Amzel L.M. Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 1999, 38:9881-9886.
10. Testa B, Kramer S.D. The biochemistry of drug metabolism-an introduction. Part 2. Redox reactions and their enzymes. Chem. Biodivers. 2007, 4:257-405.
11. Ross D. Functions and distribution of NQO1 in human bone marrow: potential clues to benzene toxicity. Chem. Biol. Interact. 2005, 153-154:137-146.
12. Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., Fauchere J.L., Delagrange P., Canet E., Boutin J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000, 275:31311-31317.
13. Vella F., Ferry G., Delagrange P., Boutin J.A. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 2005, 71:1-12.
14. Mailliet F., Ferry G., Vella F., Thiam K., Delagrange P., Boutin J.A. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett. 2004, 578:116-120.
15. Leclerc V., Yous S., Delagrange P., Boutin J.A., Renard P., Lesieur D. Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J. Med. Chem. 2002, 45:1853-1859.
16. Mailliet F., Ferry G., Vella F., Berger S., Coge F., Chomarat P., Mallet C., Guenin S.P., Guillaumet G., Viaud-Massuard M.C., Yous S., Delagrange P., Boutin J.A. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem. Pharmacol. 2005, 71:74-88.
17. Boussard M.F., Truche S., Rousseau-Rojas A., Briss S., Descamps S., Droual M., Wierzbicki M., Ferry G., Audinot V., Delagrange P., Boutin J.A. New ligands at the melatonin binding site MT(3). Eur. J. Med. Chem. 2006, 41:306-320.
18. Ettaoussi M., Peres B., Klupsch F., Delagrange P., Boutin J.A., Renard P., Caignard D.H., Chavatte P., Berthelot P., Lesieur D., Yous S. Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg. Med. Chem. 2008, 16:4954-4962.
19. Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T.C., Wu J.M., Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43:11417-11426.
20. Boutin J.A., Chatelain-Egger F., Vella F., Delagrange P., Ferry G. Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem. Biol. Interact. 2005, 151:213-228.
21. Boutin J.A., Marcheteau E., Hennig P., Moulharat N., Berger S., Delagrange P., Bouchet J.P., Ferry G. MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate. J. Pineal Res. 2008, 45:524-531.
22. Mailliet F., Audinot V., Malpaux B., Bonnaud A., Delagrange P., Migaud M., Barrett P., Viaud-Massuard M.C., Lesieur D., Lefoulon F., Renard P., Boutin J.A. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem. Pharmacol. 2004, 67:667-677.
23. Vincent L., Cohen W., Delagrange P., Boutin J.A., Nosjean O. Molecular and cellular pharmacology of 5-methoxy-carbonylamino-N-acetyltryptamine (MCA-NAT), a non-specific MT3 binding site ligand. J. Pineal Res. 2010, 48:222-229.
24. Cer R.Z., Mudunuri U., Stephens R., Lebeda F.J. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res. 2009, 37:W441-W445.
25. Kwiek J.J., Haystead T.A., Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 2004, 43:4538-4547.
26. Cadenas E., Hochstein P., Ernster L. Pro- and antioxidant functions of quinones and quinone reductases in mammalian cells. Adv. Enzymol. Relat. Areas Mol. Biol. 1992, 65:97-146.
27. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol. 1995, 49:127-140.
28. Hosoda S., Nakamura W., Hayashi K. Properties and reaction mechanism of DT diaphorase from rat liver. J. Biol. Chem. 1974, 249:6416-6423.
29. Maiti A., Reddy P.V., Sturdy M., Marler L., Pegan S.D., Mesecar A.D., Pezzuto J.M., Cushman M. Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J. Med. Chem. 2009, 52:1873-1884.
30. Celli C.M., Tran N., Knox R., Jaiswal A.K. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem. Pharmacol. 2006, 72:366-376.
31. Boutin J.A. Indirect evidences of UDP-glucuronosyltransferase heterogeneity: how can it help purification?. Drug Metab. Rev. 1987, 18:517-551.
32. Ma Q., Lu A.Y. The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters. Curr. Drug Metab. 2008, 9:374-383.
33. Calamini B., Santarsiero B.D., Boutin J.A., Mesecar A.D. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem. J. 2008, 413:81-91.
34. Wang Z, Hsieh T.C., Zhang Z., Ma Y., Wu J.M. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem. Biophys. Res. Commun. 2004, 323:743-749.
35. Pezzuto J.M. Resveratrol as an inhibitor of carcinogenesis. Pharm. Biol. 2008, 46:443-573.
36. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell. Mol. Life Sci. 2008, 65:2001-2018.
37. Maiti A, Reddy P.V., Sturdy M., Marler L., Pegan S.D., Mesecar A.D., Pezzuto J.M., Cushman M. Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J. Med. Chem. 2009, 52:1873-1884.
38. Linnane A.W., Kios M., Vitetta L. Coenzyme Q(10)-its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion 2007, 7(Suppl.):S51-S61.
39. King M.S., Sharpley M.S., Hirst J. reduction of hydrophilic ubiquinones by the flavin in tmitochondria NADH:ubiquinone oxidoreductase (complex I) and production of reactive oxygen species. Biochemistry 2009, 48:2053-2062.
40. Long D.J., Iskander K., Gaikwad A., Arin M., Roop D.R., Knox R., Barrios R., Jaiswal A.K. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J. Biol. Chem. 2002, 277:46131-46139.
41. Chomarat P., Coge F., Guenin S.P., Mailliet F., Vella F., Mallet C., Giraudet S., Nagel N., Leonce S., Ferry G., Delagrange P., Boutin J.A. Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference. Biochimie 2007, 89:1264-1275.
42. Thor H., Smith M.T., Hartzell P., Bellomo G., Jewell S.A., Orrenius S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. J. Biol. Chem. 1982, 257:12419-12425.
43. Formentini L., Moroni F., Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem. Pharmacol. 2009, 77:1612-1620.